AbbVie (ABBV) Consolidated Net Income (2012 - 2026)
AbbVie (ABBV) reported Consolidated Net Income of $697.0 million for Q1 2026, down 45.93% year-over-year from $1.3 billion in Q1 2025, and down 61.6% quarter-over-quarter from $1.8 billion in Q4 2025.
AbbVie (ABBV) Consolidated Net Income (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Consolidated Net Income data on file, last reported at $697.0 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at $697.0 million, down 45.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 13.37% YoY), and the FY2025 annual result was $4.2 billion, down 1.24% from the prior year.
- Consolidated Net Income slipped to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
- Over five years, Consolidated Net Income peaked at $4.5 billion in Q1 2022 and troughed at -$97.0 million in Q1 2023.
- A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income tumbled 102.79% in 2024, then surged 7991.3% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at $2.5 billion in 2022, then sank by 66.67% to $824.0 million in 2023, then plunged by 102.79% to -$23.0 million in 2024, then surged by 7991.3% to $1.8 billion in 2025, then tumbled by 61.6% to $697.0 million in 2026.
- Business Quant data shows ABBV's Consolidated Net Income at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $188.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 188.00 Mn |
| Jun 30, 2025 | 941.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -23.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 824.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | -97.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 928.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.05 Bn |
| Sep 30, 2021 | 3.18 Bn |
| Jun 30, 2021 | 769.00 Mn |